

Editorial

This year the *Journal of Pharmaceutical and Biomedical Analysis* enters a new stage in its development, with the larger page, double-column format and a new production style. These changes reflect a number of current trends in scientific publishing, namely the need to utilize space as effectively as possible and with the greatest clarity. The larger page size brings the *Journal of Pharmaceutical and Biomedical Analysis* into line with its sister Journals published by Pergamon, *Talanta* and *Spectrochimica Acta B*. This, together with a 30% increase in page budget, reflects the increasing demand for the *Journal* as one of the major international publications in the field.

The American Office which was established 1 year ago in Kansas under the leadership of Dr Christopher Riley has now become the focal point for all papers submitted in North America. We are delighted to report that excellent relations have been established with several of the most influential professional

bodies in the United States, and in particular with the Analytical and Pharmaceutical Quality section of the American Association of Pharmaceutical Scientists.

We wish to express our thanks to the retiring members of the Editorial Advisory Board and our special thanks are also due to Mr Peter Henn, who was instrumental in establishing the *Journal* some 9 years ago. His duties have taken him to other areas so that we now welcome the new Editorial Director for the *Journal*, Dr Peter Shepherd. We also welcome a number of new members of the Editorial Advisory Board and look forward to their enthusiastic contribution in developing the *Journal* as one of the key publications for the development of pharmaceutical and biomedical sciences in the 1990s.

Anthony F. Fell
Christopher M. Riley